Short Interest in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Drops By 17.0%

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 5,030,000 shares, a decline of 17.0% from the February 28th total of 6,060,000 shares. Currently, 10.0% of the company's stock are sold short. Based on an average daily trading volume, of 555,900 shares, the days-to-cover ratio is presently 9.0 days.

Insider Activity

In related news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Raiffeisen Bank International AG bought a new stake in Supernus Pharmaceuticals during the 4th quarter valued at approximately $25,000. Versant Capital Management Inc lifted its holdings in shares of Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after buying an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $42,000. Smartleaf Asset Management LLC grew its stake in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after acquiring an additional 870 shares during the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new position in Supernus Pharmaceuticals during the fourth quarter worth $52,000.

Analysts Set New Price Targets

Several research analysts have recently commented on SUPN shares. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday.

Supernus Pharmaceuticals Stock Up 0.8 %

SUPN stock traded up $0.25 during midday trading on Friday, hitting $32.74. 1,501,832 shares of the company traded hands, compared to its average volume of 485,366. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $40.28. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 30.60 and a beta of 0.84. The business has a 50 day simple moving average of $34.57 and a 200-day simple moving average of $35.04.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.